Skip Ribbon Commands
Skip to main content

Terumo to Increase Production Capacity for Alliance Business

​Capital Investment of 2 Billion Yen in Terumo Yamaguchi D&D for Pre-filled Syringes

20/09/2019 - TOKYO, JAPAN

Terumo Corporation (TSE: 4543) today announced that it will construct an additional production facility for pre-filled syringes at the headquarter plant of Terumo Yamaguchi D&D Corporation, a Terumo subsidiary. The capital investment for the project will total approximately JPY 2 billion. The investments announced today and on July 9, 2018 will increase the production capacity at Terumo Yamaguchi D&D by approximately 2.5 times compared to the current capability.


Terumo Yamaguchi D&D Corporation operates a plant that produces Drug and Device (D&D) products, which combines medical devices with pharmaceutical drugs in a single product. The plant manufactures D&D products such as Hulio™ (adalimumab biosimilar)*1, which is currently available in Europe, and Teribone™ 28.2 µg subcutaneous autoinjector*2, which will be marketed in Japan.


The Alliance Division offers advanced devices to pharmaceutical companies, utilizing the experience and expertise Terumo has built up through years of prefilled device manufacturing. Every drug not only differs in its effects, but also has varying characteristics and usage situations. Terumo develops tailor made drug administration devices, such as syringes and needles materials suitable to each drug. Terumo also provides contract manufacturing, which leverages the company's advanced manufacturing technology of drug delivery device and combination product. The annual revenue ended March 2019 of the Alliance Division was JPY 20.4 billion, which was 30% growth year-on-year and contributed greatly to the overall Terumo group growth. The division is expected as the growth driver force for the General Hospital Company.



*2: The product of Asahi Kasei Pharma Corporation


About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with approximately US$6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.